MarketPulse

essential thrombocythemia

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Alethio Therapeutics

Alethio Therapeutics Unveils First Mutation-Agnostic Antibody for $2B Essential Thrombocythemia Market

Alethio Therapeutics unveils ATX-011, a first-in-class antibody for treating Essential Thrombocythemia, with IND submission targeted for Q1 2027 and clinical data expected H1 2028.
AZNmonoclonal antibodyclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Pegasys Market Poised for Growth Despite DAA Competition and Tariff Headwinds

Pegasys market projected for growth via rising hepatitis B prevalence and indication expansion, though direct-acting antivirals and tariff pressures pose challenges. Asia-Pacific represents fastest-growing region.
PFERHHBYGRFSemerging marketsoncology